Fig. 8From: siRNA treatment targeting integrin α11 overexpressed via EZH2-driven axis inhibits drug-resistant breast cancer progressionSchematic diagram unraveling the regulatory mechanism and clinical implications of integrin α11 upregulation in drug-resistant breast cancerBack to article page